It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Amid a decade-high surge in drug shortages, the American Medical Association has adopted new policy measures aimed at addressing the crisis.

Novo and Lilly also market their GLP-1s for weight loss under, respectively, Wegovy (semaglutide) and Zepbound (tirzepatide). "In most countries, especially in low-income and middle-income countries, ...

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

US equities overcame brief spells of volatility to reach new all-time highs in Q3 as underlying earnings growth remained positive. Read more here.

(Irwin, 11/13) Yahoo Finance: Hims & Hers Launches GLP-1 Tracker In Response To FDA's Shortage Decision Hims & Hers is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s ...

“The paper outlines the needs are not only there, but growing over time.” New drugs for diabetes known as GLP-1s, such as ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

A 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a ...